期刊
ONCOGENE
卷 36, 期 12, 页码 1669-1677出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2016.386
关键词
-
资金
- DAMD New Investigator Award [W81XWH-11-1-0259]
- NIH [R01 NS28840]
Neurofibromatosis type 1 (NF1) is an inherited disease in which affected patients are predisposed to develop benign Schwann cell (SC) tumours called neurofibromas. In the mouse, loss of Nf1 in the SC lineage causes neurofibroma formation. The tyrosine kinase receptor EGFR is expressed in Schwann cell precursors (SCP), which have been implicated in plexiform neurofibroma initiation. To test if EGFR activity affects neurofibroma initiation, size, and/or number, we studied mice expressing human EGFR in SCs and SCP in the context of mice that form neurofibromas. Neurofibroma number increased in homozygous CNP-hEGFR mice versus heterozygous littermates, and neurofibroma number and size increased when CNP-hEGFR was crossed to Nf1(fl/fl); DhhCre mice. Conversely, diminished EGFR signalling in Nf1(fl/fl); DhhCre; Wa2/+ mice decreased neurofibroma number. In vivo transplantation verified the correlation between EGFR activity and neurofibroma formation. Mechanistically, expression of CNP-hEGFR increased SCP/neurofibroma-initiating cell self-renewal, a surrogate for tumour initiation, and activated P-Stat3. Further, Il-6 reinforced Jak2/ Stat3 activation in SCPs and SCs. These gain-and loss-of function assays show that levels of tyrosine kinase expression in SCPs modify neurofibroma initiation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据